Advertisement

ACIP Recommends 13-Valent Pneumococcal Vaccine for Elders — Physician’s First Watch

Medical News |
August 15, 2014

ACIP Recommends 13-Valent Pneumococcal Vaccine for Elders

By Joe Elia

Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS

The CDC's Advisory Committee on Immunization Practices has recommended Prevnar 13 pneumococcal vaccine for adults aged 65 and older, even if they've already received Pneumovax 23, Reuters reports.

ACIP recommends that unvaccinated elders should receive a dose of Prevnar 13, followed by a dose of Pneumovax 23; the committee further advises that those who've already received Pneumovax should receive a dose of Prevnar.

According to Reuters, ACIP voiced concerns that Medicare could not currently reimburse patients for the two-vaccine regimen. A Medicare official told the committee that the federal insurance program would evaluate its rules, but implied a revision would not take effect before January 2016.

In July, the New York Times examined the increasing costs of vaccines, singling out Prevnar 13 at $136 per shot.

Reader Comments (2)

CAROL VASSAR Physician, Internal Medicine, pvt practice

below is footnote 8 from the CDC web site. The purple immunization recommendation appears to be for adults with the specific conditions listed rather than for all adults over 19 including those >65.

Pneumococcal conjugate (PCV13) vaccination
Adults aged 19 years or older with immunocompromising conditions (including chronic renal failure and nephrotic syndrome), functional or anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants who have not previously received PCV13 or PPSV23 should receive a single dose of PCV13 followed by a dose of PPSV23 at least 8 weeks later.
Adults aged 19 years or older with the aforementioned conditions who have previously received 1 or more doses of PPSV23 should receive a dose of PCV13 one or more years after the last PPSV23 dose was received. For adults who require additional doses of PPSV23, the first such dose should be given no sooner than 8 weeks after PCV13 and at least 5 years after the most recent dose of PPSV23.
When indicated, PCV13 should be administered to patients who are uncertain of their vaccination status history and have no record of previous vaccination.
Although PCV13 is licensed by the U.S. Food and Drug Administration for use among and can be administered to persons aged 50 years or older, ACIP recommends PCV13 for adults aged 19 years or older with the specific medical conditions noted above.

Michael Metzlet, MD Colorado

Reason for 13 valent and 23 valent

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement